Market Research Logo

Pharma Wholesale and Distribution Market Forecasts 2017-2027

Pharma Wholesale and Distribution Market Forecasts 2017-2027

The pharma wholesale and distribution market is estimated at $893.69bn in 2016 and is expected to grow at a CAGR of 6.0% in the first half of the forecast period. The market is expected to grow at a CAGR of 5.2% from 2017-2027. In 2016, the branded drugs submarket held 79.5% share of the pharma wholesale and distribution market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 265-page report you will receive 83 tables and 97 figures – all unavailable elsewhere.

The 265-page report provides clear detailed insight into the pharma wholesale and distribution market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Pharma Wholesale and Distribution market forecasts from 2017-2027

This report also breaks down the revenue forecast for main submarkets:

  • Branded Drugs
  • Generic Drugs
  • Other Medicines
This report provides individual revenue forecasts to 2027 for these national markets:
  • The US
  • Japan
  • Germany
  • France
  • Italy
  • Spain
  • The UK
  • China
  • Brazil
  • Russia
  • India
Our study includes SWOT and STEP analysis of this industry and market.

Our study discusses the selected leading companies that are the major players in the pharma wholesale and distribution industry:
  • McKesson
  • Cardinal Health
  • AmerisourceBergen
  • Walgreens Boots Alliance
  • MEDIPAL HOLDINGS
  • The PHOENIX Group
  • SINOPHARM
  • Alfresa Holdings
  • SUZUKEN
  • Shanghai Pharmaceutical Holdings
Our report explains issues, events and shifts affecting that industry and market from 2016, including these influences:
  • Roles of pharmaceutical wholesalers – activities, changes and prospects
  • Revenues, costs and profits
  • Direct-to-pharmacy (DTP) activities
  • Full-line wholesalers (FLWs), short-line wholesalers (SLWs) and the drug distribution chain, including logistical service providers
  • Technologies and services – progress in supplying pharmacies, clinics and hospitals, serving healthcare professionals, governments, payers and patients
  • Forward buying, fee-for-service systems and the rise of retail pharmacies.
Our investigation also discusses other aspects of that industry, including these forces:
  • Parallel trade – activities, policies, challenges and effects
  • Inventory management agreements, clawback, reimbursement and discounts
  • Rise of specialty medicines, including biologics, vaccines and biosimilars – opportunities for intermediaries, including cold chain distribution networks
  • Actions against drug counterfeiting – security of pharmaceutical supply chains
  • Changes to regulations and healthcare budgets – policies affecting trade
Visiongain’s study is intended for anyone requiring commercial analyses for the pharma wholesale and distribution market. You find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


1. Report Overview
1.1 Global Pharma Wholesale and Distribution Industry and Market Overview
1.2 Benefits of This Report
1.3 How This Report Delivers
1.4 Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Introduction to Pharma Wholesale and Distribution
2.1 The Role of Pharmaceutical Wholesalers: The Middlemen of the Pharmaceutical Industry
2.1.1 Full-Line Wholesalers (FLWs)
2.1.2 Short-Line Wholesalers (SLWs)
2.2 The Chain of Distribution: Wholesalers vs. Logistic Service Providers
2.2.1 Secondary Wholesalers
2.2.2 Direct-to-Pharmacy (DTP) Distribution is Becoming More Prevalent
2.2.3 Major Wholesalers: Distribution of a Large Number of Products to Generate High Profits
2.2.4 Distribution from Large to Small Wholesalers: A Lengthy Distribution Chain
2.2.5 Pharmacy Benefit Managers
2.3 Generative Revenue and Profit
2.3.1 Forward Buying to Avoid Price Increases
2.3.2 Fee-for-Service: A Clear Pricing Structure
2.3.3 Discounts: Incentives for Prompt Payment or Bulk Purchases
2.3.4 Reimbursement and Wholesalers
2.3.5 Clawback: The Recovery of Reimbursement Costs by Governments
2.3.6 Parallel Trade: Different Attitudes in Europe and the US
3. The World Pharmaceutical Wholesale and Distribution Market: 2016-2027
3.1 The World Pharmaceutical Wholesale and Distribution Market in 2015, Restricted by Government Price Reductions and Generic Substitution
3.2 The Pharmaceutical Wholesale and Distribution Industry: World Market Forecast, 2016-2027
3.3 Branded and Generic Drugs: Revenue vs. Profit, 2016-2027
3.3.1 Branded and Generic Drugs: Revenue Generation, 2016
3.3.2 Branded Drugs: Revenue Forecast, 2016-2027
3.3.3 Generic Drugs: Revenue Forecast, 2016-2027
4. Pharmaceutical Wholesale and Distribution Industry: Leading National Markets, 2016-2027
4.1 The Leading National Markets: the US Dominates in 2016
4.2 The Future of the Leading National Markets: Will the US Continue to Dominate the Market?
4.3 The US Pharma Wholesale and Distribution Market
4.3.1 The Budget Control Act and its Effect on the US Wholesale and Distribution Industry
4.3.2 Legislation to Prevent Counterfeit Drugs Can Differ Between States
4.3.3 An Increase in Fee-For-Service Activity
4.3.4 Pharma Wholesale and Distribution Market in the US: Market Forecast, 2016-2027
4.4 The Leading European (EU5) Pharma Wholesale and Distribution Markets
4.4.1 The Difference Between the US and European Markets
4.4.2 State-Funded Healthcare and Reimbursement
4.4.3 EU5: Market Forecast, 2016-2027
4.4.4 Germany: Pharma Wholesale and Distribution Market, 2016
4.4.5 France: Pharma Wholesale and Distribution Market, 2015
4.4.6 Italy: Pharma Wholesale and Distribution Market, 2016
4.4.7 Spain: Pharma Wholesale and Distribution Market, 2016
4.4.8 UK: Pharma Wholesale and Distribution Market, 2016
4.5 Japan: Pharma Wholesale and Distribution Market, 2016
4.5.1 Drug Pricing and Performing Fees in Japan
4.5.2 Japan: Pharma Wholesale and Distribution Market Forecast, 2016-2027
4.6 China: Pharma Wholesale and Distribution Market, 2016
4.6.1 China: Leading Pharma Wholesale and Distribution Companies, 2016
4.6.2 China: Pharma Wholesale and Distribution Market Forecast, 2016-2027
4.7 Brazil: Pharma and Wholesale Distribution Market, 2016
4.7.1 Drug Price Controls in Brazil
4.7.2 Brazil: Leading Pharma Wholesale and Distribution Companies, 2016
4.7.3 Brazil: Pharma Wholesale and Distribution Market Forecast, 2016-2027
4.8 India: Pharma Wholesale and Distribution Market, 2016
4.8.1 India: Pharma Wholesale and Distribution Market Forecast, 2016-2027
4.9 Russia: Pharma Wholesale and Distribution Market, 2016
4.9.1 Drug Pricing Controls in Russia
4.9.2 Market Trends in Russia
4.9.3 Russia: Pharma Wholesale and Distribution Market Forecast, 2016-2027
4.10 Conclusion
5. Leading Pharma Wholesalers and Distributors In 2016: Current and Future Performance
5.1 The Leading Pharma Wholesalers and Distribution Companies in 2016
5.2 Revenue vs. Profit
5.3 Leading Pharma Wholesale and Distribution Companies: Grouped Forecasts, 2016-2027
5.4 McKesson: The Oldest and Largest Healthcare Services Company in the US
5.4.1 McKesson: Historical Performance, 2010-2015
5.4.2 Future Strategies: Consummate Acquisitions to Complement Existing Business or Expand Businesses
5.4.3 McKesson: Revenue Forecast, 2016-2027
5.5 Cardinal Health: The World’s Third Largest Pharma Wholesaler
5.5.1 Cardinal Health: Historical Performance, 2010-2015
5.5.2 Will CVS Joint Venture and Acquisitions Stimulate Future Growth?
5.5.3 Cardinal Health: Revenue Forecast, 2016-2027
5.6 AmerisourceBergen: Third Largest Global Pharma Wholesaler and Distributor
5.6.1 AmerisourceBergen: Historical Performance, 2016
5.6.2 Will Contracts with Walgreens and Alliance Boots Drive Future Growth?
5.6.3 AmerisourceBergen: Revenue Forecast, 2016-2027
5.7 Walgreens Boots Alliance: The Largest Drugstore Chain in the US and Global Wholesale and Distribution Network
5.7.1 Walgreens Boots Alliance: Historical Performance, 2011-2016
5.7.2 Acquisitions and Future Strategies of Walgreens Boots Alliance
5.7.3 Walgreens Boots Alliance: Revenue Forecast, 2016-2027
5.8 MEDIPAL HOLDINGS CORPORATION: Japan’s Leading Pharmaceutical Wholesaler
5.8.1 MEDIPAL HOLDINGS CORPORATION: Historical Performance, 2011-2015
5.8.2 Future Strategies of MEDIPAL HOLDINGS CORPORATION: Revised Business Portfolio with Diverse Sources of Earnings
5.8.3 MEDIPAL HOLDINGS CORPORATION: Revenue Forecast, 2016-2027
5.9 Phoenix Group: Biggest European Wholesalers
5.9.1 The PHOENIX Group: Historical Performance, 2011-2015
5.9.2 Future Strategies of the PHOENIX Group: Selective Acquisition
5.9.3 The PHOENIX Group: Revenue Forecast, 2016-2027
5.10 SINOPHARM: The Leading Pharmaceutical Wholesaler and Distributor in China
5.10.1 SINOPHARM: Historical Performance, 2011-2016
5.10.2 Future Strategies of SINOPHARM: Provide Comprehensive Services and Wider Business Coverage
5.10.3 SINOPHARM: Revenue Forecast, 2016-2027
5.11 Alfresa Holdings: Second Largest Pharmaceutical Wholesaler and Distributor in Japan
5.11.1 Alfresa Holdings: Historical Performance, 2011-2016
5.11.2 Future Strategy of Alfresa Holdings: To Focus on Expanding Business Fields and Increasing Footprint
5.11.3 Alfresa Holdings: Revenue Forecast, 2016-2027
5.12 SUZUKEN CO., LTD: The First Nationwide Wholesaler of Japan
5.12.1 SUZUKEN CO. LTD: Historical Performance, 2011-2015
5.12.2 Future Strategies of SUZUKEN CO., LTD: Five Growth Initiatives and Special Focus on Diabetes Field
5.12.3 SUZUKEN CO., LTD: Revenue Forecast, 2016-2027
5.13 Shanghai Pharmaceuticals Holding: China’s Second Largest Wholesaler
5.13.1 Shanghai Pharmaceuticals Holding: Historical Performance, 2011-2015
5.13.2 Future Strategies of Shanghai Pharma: Expansion of Three Leading Regions in China
5.13.3 Shanghai Pharma: Revenue Forecast, 2016-2027
6. Qualitative Analysis of the Pharma Wholesale and Distribution Market
6.1 The Strengths and Weaknesses of the Pharma Wholesale and Distribution Market, 2016
6.1.1 The Insatiable Demand for Drugs: A Recession Proof Industry?
6.1.2 Wholesalers Do More than Deliver Drugs
6.1.3 Large Companies Dominate the Market
6.1.4 Despite High Revenues, Profit Margins Are Low
6.1.5 Government-Induced Drug Price Pressures Restrict Profits
6.1.6 The Problem of Counterfeit Drugs
6.2 The Opportunities and Threats of the Pharma Wholesale and Distribution Market, 2016-2027
6.2.1 The Demand for Pharmaceuticals is Increasing
6.2.2 The Increasing Use of speciality Drugs Will Drive Growth
6.2.3 The Increasing Use of Generic Drugs Will Limit Revenue, But Drive Profit Generation
6.2.4 The Promotion of Drug Therapy in the US
6.2.5 Globalisation: The Major National Markets are Dominated by Few Companies
6.2.6 Increased Adoption of the DTP Distribution Model
6.2.7 The Threat of Healthcare Budget Cuts
6.2.8 Do Large Pharmacy Chains Pose a Threat?
6.2.9 Does the Diversion and Re-Importation of Medicines Pose a Threat to the Industry?
6.2.10 The Threat of Industry Consolidation
6.3 Social, Technological, Economical and Political Factors Influencing the Market, 2016-2027 (STEP Analysis)
6.3.1 Political Factor: The Impact of Recent Regulatory Changes in the EU
6.3.2 Political Factor: Combating Counterfeit Medicines
7. Conclusions
7.1 The Future of the Pharma Wholesale and Distribution Market
7.2 The Leading National Pharma Wholesale and Distribution Markets
7.3 The Leading Companies in the Pharma Wholesale and Distribution Industry
7.4 Trends in the Pharma Wholesale and Distribution Industry
7.4.1 Generics Will Threaten Revenue
7.4.2 Manufacturers Will Deliver More Drugs Directly
7.4.3 There Will Be Greater Demand for Speciality Medicines
7.4.4 Consolidation Will Drive Growth
7.4.5 Anti-Counterfeiting Demands Will Add to Wholesalers’ Costs
Associated Visiongain Reports
Visiongain REPORT SALES ORDER FORM
APPENDIX A
About Visiongain
APPENDIX B
Visiongain report evaluation form
List of Tables
Table 1.1 Foreign Currency Exchange Rates to $US, 2016
Table 2.1 Use of DTP Model in the UK, 2007-2012
Table 3.1 Pharmaceutical Wholesale and Distribution: World Market Forecast ($bn), AGR (%), CAGR (%), 2016-2027
Table 3.2 Pharmaceutical Wholesale and Distribution: Branded Drugs, Generic Drugs and Others, Revenue ($bn) Forecasts, AGR (%), CAGR (%) and Market Shares (%), 2016-2027
Table 3.3 Wholesale and Distribution of Branded Drugs: Revenue ($bn) and Market Share (%) Forecast, 2016-2027
Table 3.4 Wholesale and Distribution of Generic Drugs: Revenue ($bn) and Market Share (%) Forecast, 2016-2027
Table 4.1 Pharma Wholesale & Distribution Leading National Markets: Revenues ($bn) and Market Share (%), 2016
Table 4.2 Pharma Wholesale & Distribution Leading National Markets: Revenue ($bn) Forecasts, AGR (%) and CAGR (%), 2016-2027
Table 4.4 US Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
Table 4.5 Price Controls in Europe, 2016
Table 4.6 EU5 Pharma Wholesale & Distribution Market: Revenue ($bn) Forecasts, AGR (%) and CAGR (%), 2016-2027
Table 4.7 German Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
Table 4.8 French Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
Table 4.9 Italian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
Table 4.10 Spanish Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
Table 4.11 UK Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
Table 4.12 Percentage of the Population Ages 60+ in the US, Europe, Japan, China and India, 2015 and 2030
Table 4.13 Japanese Pharmaceutical Wholesale and Distribution Market: Drug Price Revision Growth (%), 2007-2016
Table 4.14 Japanese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
Table 4.15 Chinese Pharma Wholesale & Distribution: Revenue ($bn) and Market Shares (%) of Leading Companies, 2016
Table 4.16 Chinese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
Table 4.17 Brazilian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
Table 4.18 Indian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
Table 4.19 Russian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2016-2027
Table 5.1 Leading Companies in the Pharmaceutical Wholesale and Distribution Market: Revenues ($bn) and Market Shares (%), 2016
Table 5.2 Leading Pharmaceutical Wholesale and Distribution Companies: Revenue Forecasts ($bn), AGR (%) and CAGR (%), 2016-2027
Table 5.3 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%) for 2016, 2021 and 2027
Table 5.4 McKesson, Distribution Solutions: Services and Customers, 2016
Table 5.5 McKesson, Technology Solutions: Services and Customers, 2016
Table 5.6 McKesson: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2010-2015
Table 5.7 McKesson: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.8 McKesson: Gross Profit ($bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.9 Acquisitions by McKesson, 2007-2017
Table 5.10 McKesson: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.11 Cardinal Health: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Operating Earnings ($bn), AGR (%) and CAGR (%), 2010-2015
Table 5.12 Cardinal Health: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.13 Cardinal Health: Operating Earnings ($bn) and Annual Growth (%) Breakdown by Business Segment, 2014-2015
Table 5.14 Cardinal Health: Revenue ($bn) and Revenue Share (%) Breakdown by Customer, 2015
Table 5.15 Selected Acquisitions by Cardinal Health and their Line of Business, 2007-2017
Table 5.16 Cardinal Health: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.17 AmerisourceBergen: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
Table 5.18 AmerisourceBergen: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
Table 5.19 AmerisourceBergen: Gross Profit ($bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
Table 5.20 AmerisourceBergen: Revenue ($bn) and Revenue Share (%) Breakdown by Customer, 2016
Table 5.21 Acquisitions by AmerisourceBergen and their Line of Business, 2007-2017
Table 5.22 AmerisourceBergen: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.23 Walgreens Boots Alliance: Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
Table 5.24 Walgreens Boots Alliance: Pharmaceutical Wholesale Revenue ($bn), AGR (%), and CAGR (%) Forecast, 2016-2027
Table 5.25 MEDIPAL Holdings: Consolidated Subsidiary Companies, 2016
Table 5.26 MEDIPAL Holdings: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
Table 5.27 MEDIPAL Holdings: Revenue (¥bn, $bn) and Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.28 MEDIPAL Holdings: Operating Income ($bn, ¥bn), Operating Income Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.29 MEDIPAL Holdings: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.30 PHOENIX Group: Subsidiary Companies, 2015
Table 5.31 PHOENIX Group: Historical Revenue (€bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (€bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
Table 5.32 PHOENIX Group: Revenue (€bn, $bn), Revenue Share (%) Breakdown by Region, 2014
Table 5.33 PHOENIX Group: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.34 SINOPHARM Group: Historical Revenue (RMBbn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (RMBbn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
Table 5.35 SINOPHARM Group: Revenue (RMBbn, $bn) and Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
Table 5.36 SINOPHARM Group: Operating Profit (RMBbn, $bn), Operating Profit Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
Table 5.37 SINOPHARM Group: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.38 Alfresa Holdings: List of Significant Subsidiaries and Affiliates, 2016
Table 5.39 Alfresa Holdings: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
Table 5.40 Alfresa Holdings: Business Strategies, 2013-2016
Table 5.41 Alfresa Holdings: Revenue (¥bn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
Table 5.42 Alfresa Holdings: Gross Profit (¥bn, $bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2015-2016
Table 5.43 Alfresa Holdings: Challenges for the 16-18 Mid-term Management Plan - Break Through to Tomorrow, 2016
Table 5.44 Alfresa Holdings: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.45 SUZUKEN: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2015
Table 5.46 SUZUKEN: Revenue (¥bn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.47 SUZUKEN: Operating Income (¥bn, $bn), Operating Income Share (%) and AGR (%) Breakdown by Business Segment, 2014-2015
Table 5.48 SUZUKEN: Revenue (¥bn, $bn), Revenue Share (%) Breakdown for Pharmaceuticals Distribution Segment by Region, 2014
Table 5.49 SUZUKEN: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2016-2027
Table 5.50 Shanghai Pharmaceuticals Holding: Historical Revenue (RMBbn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (RMBbn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2016
Table 5.51 Shanghai Pharmaceuticals Holding: Revenue (RMBbn, $bn), Revenue Share (%) and AGR (%)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report